The IDH3B antibody is a crucial tool for studying the isocitrate dehydrogenase 3 beta subunit (IDH3B), a component of the IDH3 enzyme complex within the tricarboxylic acid (TCA) cycle. IDH3 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), a reaction essential for cellular energy production and redox balance. Unlike the NADP-dependent IDH1 and IDH2 isoforms, IDH3 is NAD+-dependent and functions exclusively in mitochondria. IDH3B, encoded by the *IDH3B* gene, forms a heterotetramer with IDH3A and IDH3G subunits, and its expression is critical for maintaining metabolic homeostasis.
Mutations in IDH family genes, particularly *IDH1* and *IDH2*, are well-documented in cancers such as gliomas and acute myeloid leukemia (AML), where they drive oncogenesis via 2-hydroxyglutarate (2-HG) accumulation. While IDH3B alterations are less commonly implicated in cancer, recent studies suggest its potential role in metabolic reprogramming and tumorigenesis. The IDH3B antibody enables the detection and quantification of IDH3B protein levels in tissues or cells, aiding research on mitochondrial dysfunction, metabolic disorders, and cancer biology.
Clinically, IDH3B antibodies are used in immunohistochemistry (IHC), Western blotting, and ELISA to assess protein expression patterns, offering insights into disease mechanisms or therapeutic responses. Their application extends to exploring IDH3B's regulatory roles in cellular differentiation, apoptosis, and oxidative stress. As interest in metabolic enzymes as therapeutic targets grows, IDH3B antibodies remain vital for elucidating the complex interplay between mitochondrial metabolism and disease.